The finding that systemic administration of ALX can recapitulate the glucose production-lowering effect of GlyT1 inhibition in the DVC during the pancreatic (basal insulin)–euglycaemic clamp setting further substantiates the potential therapeutic relevance of GlyT1 inhibitors in diabetes and obesity. This evidence concerns the gene INS and obesity disorder.